Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy

Talotta, Rossella; Atzeni, Fabiola; Laska, Magdalena Janina

doi:10.1080/13543784.2020.1777983

Cited by 7 publications

(4 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…"Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. " [98] After reading the title, Sarah has many questions -What is the paper about? What are therapeutic peptides?…”

Section: Paper Plain Designmentioning

confidence: 99%

“…The scenarios for each paper were drawn from §3.0.2. For each scenario, we selected a single paper ( [98] for SLE and [8] for a herniated disc) for participants to read based on the most common papers readers selected in §3.…”

Section: Usability Studymentioning

confidence: 99%

“…Drawing on this work as inspiration, we ask what combination of affordances would be necessary to help bridge the often enormous gap between a reader's current knowledge of biomedical research and the contents of a paper. Consider, for instance, this sentence from a recent article about systemic lupus erythematosus, linked to from a patient-facing MedlinePlus page [98]:…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Paper Plain: Making Medical Research Papers Approachable to Healthcare Consumers with Natural Language Processing

August¹,

Wang²,

Bragg³

et al. 2022

Preprint

View full text Add to dashboard Cite

When seeking information not covered in patient-friendly documents, like medical pamphlets, healthcare consumers may turn to the research literature. Reading medical papers, however, can be a challenging experience. To improve access to medical papers, we introduce a novel interactive interface-Paper Plain 1 -with four features powered by natural language processing: definitions of unfamiliar terms, in-situ plain language section summaries, a collection of key questions that guide readers to answering passages, and plain language summaries of the answering passages. We evaluate Paper Plain, finding that participants who use Paper Plain have an easier time reading and understanding research papers without a loss in paper comprehension compared to those who use a typical PDF reader. Altogether, the study results suggest that guiding readers to relevant passages and providing plain language summaries, or "gists, " alongside the original paper content can make reading medical papers easier and give readers more confidence to approach these papers. CCS Concepts: • Human-centered computing → Empirical studies in interaction design; Interactive systems and tools; User studies.

show abstract

Section: Paper Plain Designmentioning

confidence: 99%

Section: Usability Studymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Paper Plain: Making Medical Research Papers Approachable to Healthcare Consumers with Natural Language Processing

August¹,

Wang²,

Bragg³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Systemic lupus erythematosus (SLE) is a common autoimmune disease that can involve multiple organs and systems (1). One of the most common complications of SLE is lupus nephritis (LN) (2).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-98-5p inhibits human mesangial cell proliferation and TNF-α and IL‑6 secretion by targeting BTB and CNC homology 1

Shi

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

MicroRNA (miR)-98-5p has been reported to be involved in the development of lupus nephritis (LN); however, its specific role in LN remains unclear. The present study aimed to investigate the effect of miR-98-5p on human mesangial cell proliferation and the secretion of TNF-α and IL-6. Reverse transcription-quantitative PCR (RT-qPCR) and western blotting were used to analyze the level of gene and protein expression, respectively. Cellular proliferation was assessed using a Cell Counting Kit-8 (CCK-8) assay. ELISA was used to detect the secretion of TNF-α and IL-6 by human mesangial cells. RT-qPCR analysis revealed that miR-98-5p expression was downregulated in LN renal tissues compared with control renal tissues. Overexpression of miR-98-5p inhibited human mesangial cell proliferation and the secretion of TNF-α and IL-6, whereas miR-98-5p-knockdown demonstrated the opposite effect. Dual luciferase reporter assays demonstrated that miR-98-5p directly targeted BTB and CNC homology 1 (BACH1). BACH1-overexpression promoted human mesangial cell proliferation and the secretion of TNF-α and IL-6, whereas BACH1-knockdown demonstrated the opposite effect. Notably, co-transfection with miR-98-5p mimic inhibited BACH1-overexpression induced human mesangial cell proliferation and the secretion of TNF-α and IL-6. The results of the present study indicated that miR-98-5p inhibited human mesangial cell proliferation and the secretion of TNF-α and IL-6 by targeting BACH1. Therefore, miR-98-5p and BACH1 may represent potential therapeutic targets for LN.

show abstract

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Karmakar,

Kumar,

Prabhu

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life. Despite several attempts to comprehend the pathogenesis of SLE, knowledge about the precise molecular mechanisms underlying this disease is still lacking. The current treatment options for SLE are pragmatic and aim to develop composite biomarkers for daily practice, which necessitates the robust development of novel treatment strategies and drugs targeting specific responsive pathways. In this communication, we review and aim to explore emerging therapeutic modalities, including multiomics-based approaches, rational drug design, and CAR-T-cell-based immunotherapy, for the management of SLE.

show abstract

Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy

Cited by 7 publications

References 138 publications

Paper Plain: Making Medical Research Papers Approachable to Healthcare Consumers with Natural Language Processing

Paper Plain: Making Medical Research Papers Approachable to Healthcare Consumers with Natural Language Processing

MicroRNA-98-5p inhibits human mesangial cell proliferation and TNF-α and IL‑6 secretion by targeting BTB and CNC homology 1

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Contact Info

Product

Resources

About